LONDON (Alliance News) - Five Prime Therapeutics, Inc announced an expansion of its respiratory disease research collaboration with GlaxoSmithKline PLC.
The collaboration was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease or COPD.
The scope of the collaboration was increased in April 2014 to include two additional respiratory disease discovery programs for a six-month evaluation period. Glaxo has now committed to continue these two discovery programs for another 18 months.
Five Prime will receive USD2 million in research funding for this expansion, USD0.5 million of which it has already received.
If Glaxo licenses a target discovered by Five Prime in the collaboration, Five Prime would also be eligible to receive up to USD193.8 million in potential option exercise fees and milestone payments, as well as tiered royalties on global net sales for each product resulting from a selected drug target.
Copyright RTT News/dpa-AFX
Glaxosmithkline (GSK)